Finally, a weight loss benefit that pays off
Embla helps employers offer weight care that works. With our behavior-led, low-dose GLP-1 approach, employees lose more weight, improve their health, and taper off medication — all while reducing long-term spend.
Proven by data. Validated in practice.
Our TRIM clinical study of nearly 2,700 participants confirms that combining behavioral support with the lowest effective GLP-1 doses leads to:
16.7% average weight loss in 12 months
66% lower medication use
8/10 experience little to none weight gain after graduating off medication
This approach leads to stronger adherence, better outcomes, and meaningful reductions in healthcare spend — especially compared to unsupported GLP-1 coverage.
16.7%
Average weight loss in 12 months
66%
66% lower average GLP-1 medication use
8/10
Successfully taper without weight regain
Impact that matters
to employers
Lower GLP-1 spend
66% less average GLP-1 use per employee through structured tapering and behavior-first care.
Better weight loss outcomes
16.7% average weight loss at 12 months, which is up to 85% more effective than GLP-1s alone.
Whole-person health gains
Improved energy, mobility, mental health, and long-term medication independence.
What your people will say
"I stayed on the lowest GLP-1 dose while focusing on movement, nutrition, and quality of life. Now my blood pressure and A1c are normal — and I’ve lost 60 pounds."
"Embla helped me lose over 100 pounds, and I didn’t feel like I was doing it alone. My coach kept me focused, even through life’s curveballs."
"Thanks to the structured coaching and support, I stopped medication 3 weeks ago and my weight is still stable. I finally feel in control."
Why it matters for your population
Even modest weight loss drives measurable health improvements:
42% lower risk of type 2 diabetes (at 13% weight loss)
Up to 50% reduction in sleep apnea symptoms (with 10–15% weight loss)
Improved mobility, energy, and quality of life
Ready to offer better weight care?
Let’s talk about how Embla can reduce GLP-1 costs and improve health outcomes across your employee population.